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ABSTRACT
In recent years there has been a signiﬁcant upsurge in research on the characterisation and veriﬁcation of
the potential health beneﬁts associated with the use of probiotics. In addition, the market for probiotics
continues to expand exponentially as consumers (mostly healthy individuals) rely on health claims
made by manufacturers to make their choices. This review appraises the available evidence for and
against the health claims associated with probiotics. The use of probiotics in promoting gastrointestinal
health and immunity, and their use in the prevention of urogenital infections, allergies and cancer are
reviewed. Furthermore, issues surrounding the use of probiotics in healthy individuals, the safety of
probiotics and regulatory concerns are addressed. There is scientiﬁc evidence that speciﬁc strains of
probiotic microorganisms confer health beneﬁts on the host and are safe for human use. However, this
evidence cannot be extrapolated to other strains, as these effects are strain-speciﬁc. Probiotics have
potential health beneﬁts for conditions such as gastrointestinal infections, genitourinary infections,
allergies and certain bowel disorders, all of which afﬂict a considerable proportion of the global
population. However, considerable work is still needed to conﬁrm these potential health beneﬁts.
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INTRODUCTION
Probiotics are deﬁned as live microorganisms
that, when administered in adequate amounts,
confer a beneﬁcial effect on the health of the host
[1]. The original observation of the positive role of
some bacteria can be credited to the pioneering
work of Metchnikoff in the early 1900s [2], which
suggested that these beneﬁcial bacteria could be
administered with a view to replacing harmful
microbes with useful ones. The term probiotic,
meaning ‘for life’, was ﬁrst coined in the 1960s by
Lilly and Stillwell [3].
In recent years, there has been an upsurge in
research into probiotics, as well as growing
commercial interest in the probiotic food concept.
This increased research has resulted in signiﬁcant
advances in our understanding and ability to
characterise speciﬁc probiotic organisms, as well
as attempts to verify their attributed health
beneﬁts. Probiotic food constitutes a sizeable part
of the functional food market [4], and continues to
grow at an exponential rate, with the potential for
market growth estimated at a staggering US$120
million per month [5,6]. However, this commer-
cial exploitation of the probiotic food concept is
still associated with a large body of unsubstanti-
ated claims. After many years of popularity in the
Japanese and European markets, manufacturers
of these products are venturing into new markets,
including the Arabian Gulf region, as evidenced
by the variety of probiotic food products now
available in supermarkets and healthfood stores.
The perception that fermented milk or yoghurt is
beneﬁcial is already widespread within this
region because, traditionally, these products have
been used by local healers for the treatment of
diverse conditions such as skin allergies, stomach
upsets, especially diarrhoea, and vaginal dis-
charges.
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However, major concerns regarding the qual-
ity, labelling and veriﬁcation of claims attributed
to some of these products still remain [7–9]. In the
UK, where 3.5 million individuals take probiotic
supplements in some form daily, a panel of
European experts found that a number of probi-
otics tested had incorrect labelling, markedly
reduced numbers of strains, and the presence of
strains not included on labels, including the
potentially pathogenic Enterococcus faecium (found
in nine products) [9]. This is a cause for concern,
and calls for an international consensus on eval-
uating the efﬁcacy and safety of these products.
PROBIOTIC MICROORGANISMS
AND FOOD PRODUCTS
Two main genera of Gram-positive bacteria,
Lactobacillus and Biﬁdobacterium, are used exten-
sively as probiotics [1,10]. However, other
genera, such as Escherichia, Enterococcus and
Saccharomyces, have also been marketed as probio-
tics [10,11], although concerns still remain regard-
ing the safe use of these organisms for this
purpose [12–14]. Current evidence indicates that
probiotic effects are strain-speciﬁc; therefore, a
beneﬁcial effect attributed to one strain cannot be
assumed to be provided by another strain, even
when it belongs to the same species [15]. Table 1
shows some of the organisms used commonly as
priobiotics.
According to recent Food and Agriculture
Organization (FAO) and WHO guidelines [1,16],
probiotic organisms used in food must be capable
of surviving passage through the gut; i.e., they
must have the ability to resist gastric juices and
exposure to bile. Furthermore, they must be able
to proliferate and colonise the digestive tract. In
addition, they must be safe and effective, and
maintain their effectiveness and potency for the
duration of the shelf-life of the product.
Dairy products, including yoghurt, fermented
milk products and cheese, remain at the forefront
of probiotic food development. There is a com-
mon perception among consumers that yoghurt
per se is a probiotic food product. Is this a fact or a
myth? Even among experts in this ﬁeld there is
still a debate about whether or not the yoghurt
starter cultures Lactobacillus bulgaricus and Strepto-
coccus thermophilus should be considered as pro-
biotics [17,18]. These organisms are sensitive to
conditions in the digestive tract and do not
achieve very high numbers in the gut, although
some beneﬁcial effects, such as improved lactose
digestion and immune system enhancement, have
been associated with their use [19]. Yoghurt with
added live probiotic strains is now available
commercially, and a number of such products
that have emerged as leaders in the European
market are now also marketed internationally. In
the USA, the National Yoghurt Association has
introduced a ‘Live Active Culture Seal’ to identify
refrigerated or frozen yoghurt products that
contain at least 108 or 107 viable lactic acid
bacteria ⁄g at the time of manufacture (http://
www.aboutyogurt.com/lacYogurt/). However,
these counts do not differentiate between
true probiotic strains and starter cultures; hence
they are still not reﬂective of true probiotic
products.
BENEFICIAL HEALTH EFFECTS OF
PROBIOTICS
Although some of the effects of probiotics have
been documented clearly, research is still ongoing
in other areas, with important questions remain-
ing unanswered. However, when considering the
potential health beneﬁts, it is crucial to remember
that different probiotic strains are associated with
different health beneﬁts. The overall body of
evidence suggests a beneﬁcial effect with the use
of certain probiotic microorganisms.
Immunity
One of the common claims used in the marketing
of probiotic products is that they help boost
immune status. Although in-vitro and in-vivo
Table 1. Examples of microorganisms that are considered
to be probiotics
Lactobacillus spp. Biﬁdobacterium spp. Others
L acidophilus B. biﬁdum Escherichia coli Nissle
L. casei B. breve Saccharomyces boulardii
L. crispatus B. infantis Streptococcus thermophilusa
L. delbrueckii subsp. bulgaricusa B. longum Enterococcus faeciumb
L. fermentum B. lactis






aThere is still debate about the probiotic activity.
bSafety concerns remain because of potential pathogenicity and vancomycin
resistance.
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studies suggest that probiotics may modulate
the immune response, the precise mechanisms
involved remain unclear [20], and studies with
probiotic preparations in different laboratories
have generated conﬂicting results. However,
available data suggest that probiotic bacteria
possess the ability to modulate the immune
system by promoting the endogenous host
defence systems. Studies have shown that probi-
otic bacteria can modify various immune param-
eters, including humoral, cellular and non-
speciﬁc immunity [21–26]. Emerging data also
indicate that probiotics enhance the activity of
natural killer cells in the elderly and modulate
non-speciﬁc host defences [10,25,27,28]. A rever-
sal of the age-related decline in cytokine produc-
tion has been demonstrated in ageing mice fed
with probiotic supplements [29]. Although the
mechanism of this reversal is unknown, it may be
related to the selective adherence of probiotics to
M-cells of Peyer’s patches [30]. Immune-modula-
ting mechanisms that have been demonstrated
with probiotics include the induction of mucus
production, macrophage activation by lactobacilli
signalling, stimulation of secretory IgA and neu-
trophils, inhibition of release of inﬂammatory
cytokines, and stimulation of elevated peripheral
immunoglobulins [31–35]. It has also been shown
that probiotics may modulate dendritic cell
surface phenotype and cytokine release [36].
However, it is unclear whether these immuno-
modulatory effects are localised or systemic. It is
not known whether these immunoregulatory
effects are similar in healthy subjects and those
with underlying disease, or whether all candidate
probiotic organisms elicit similar effects on the
immune system. Current evidence suggests that
the regulatory effects on the immune system
might be different in healthy subjects compared
to those with underlying disease, since it has
been reported that probiotics have a stimulatory
effect on phagocytosis in healthy subjects, but
cause downregulation in patients with allergy
[37]. In addition, other available data suggest that
these immunomodulatory effects may depend on
the immune status of the host and the dose of
probiotics given, and that differences may exist
between speciﬁc strains [22,26,32,38,39]. Clearly,
more research is required to characterise the
immunomodulatory properties of candidate pro-
biotic bacteria and to tailor their application for
speciﬁc target populations.
Diarrhoea
The beneﬁcial effect of probiotics in reducing the
incidence or duration of certain diarrhoeal illnes-
ses is perhaps the most substantiated health claim
to date [20,40,41]. This is especially true for the
use of Lactobacillus rhamnosus GG, Biﬁdobacterium
lactis BB-12 and Lactobacillus reuteri SD2222 in the
prevention and treatment of rotavirus diarrhoea
in children [42–47]. A signiﬁcant reduction in the
duration of diarrhoea and earlier hospital dis-
charge was demonstrated in several trials using
L. rhamnosus GG [20,41]. In addition, prophylactic
use in hospitalised children resulted in a reduc-
tion in the risk of acquiring nosocomial diarrhoea
[48]. In undernourished children, the preven-
tive effect was greatest in the group aged
18–29 months, and was seen mainly in non-
breast-fed children [49]. Mechanisms that have
been proposed for this protective effect include
competitive blockage of receptor sites (resulting
in inhibition of virus adherence and invasion),
enhancement of the host immune system, and
production of substances that inactivate virus
particles [20]. However, none of these mecha-
nisms has been demonstrated conclusively.
Nevertheless, it is now suggested that there is
sufﬁcient evidence to recommend the use of
L. rhamnosus GG in milk or capsule form as an
adjunct to oral rehydration therapy for the treat-
ment of rotavirus diarrhoea [35,50,51]. It is
estimated that a child dies every 15 s from
diarrhoeal disease. The implementation of such
a recommendation, particularly in developing
countries, could contribute signiﬁcantly to redu-
cing the morbidity and mortality associated with
diarrhoea.
In contrast, the beneﬁcial effect of probiotics for
bacterial diarrhoea, particularly antibiotic-associ-
ated diarrhoea and travellers’ diarrhoea, remains
unproven, as results from a number of studies are
conﬂicting [52–57]. While L. rhamnosus GG has
been shown to be useful in the prevention of
antibiotic-associated diarrhoea in children, sim-
ilar effects were not observed in adults [54,56]. A
number of studies have evaluated the effect
of Saccharomyces boulardii in the prevention of
antibiotic-associated diarrhoea, but the results
have been inconclusive, as the reduced incidence
seen in some studies was not demonstrable in
others [57]. In addition, a beneﬁcial effect in
Clostridium difﬁcile infection was demonstrable
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only when S. boulardii was combined with high-
dose vancomycin [58].
Necrotising enterocolitis is a cause of morbidity
and mortality in pre-term babies. In a retrospec-
tive comparison study, the treatment of pre-term
babies with a combination of two probiotic strains
(Lactobacillus acidophilus and Biﬁdobacterium infan-
tis) was effective in reducing the occurrence of
necrotising enterocolitis and associated mortality
[59]. However, another study using Lactobacillus
alone did not show a statistically signiﬁcant
reduction in the occurrence of necrotising entero-
colitis [60]. A number of commercial infant milk
formulas contain added probiotics. While there
may be beneﬁcial effects, the use of probiotics so
early in life, and at a time when the gut micro-
biota has not yet been established, might result in
long-term colonisation with these organisms. The
implications of modifying the complex intestinal
microbial ecosystem are still unclear, and a better
understanding of the effects of these interventions
on the infant gut microbiota is needed.
Other gastrointestinal conditions
Various studies have assessed the efﬁcacy of
probiotics for the prevention and treatment of
other common gastrointestinal conditions, inclu-
ding Helicobacter pylori infection and inﬂamma-
tory bowel diseases, such as Crohn’s disease and
irritable bowel syndrome [41,61–64]. Although
animal studies and preliminary human studies
have shown promising results, large double-
blinded randomised trials are required to verify
the beneﬁts of probiotic products in treating these
conditions. In addition, there is evidence to
suggest that the intestinal microbiota play a
critical role in the pathogenesis of bowel inﬂam-
matory disease, and it appears that the use of a
combination rather than a single probiotic strain
might be effective in alleviating the symptoms
[20].
Cancer
There is accumulating evidence to suggest that
some members of the intestinal microbiota inﬂu-
ence the onset of carcinogenesis by producing
enzymes, such as glycosidase, azoreductase,
nitroreductase and b-glucoronidase, which trans-
form pre-carcinogens into active carcinogens
[65,66]. Preliminary data suggest that probiotic
products may protect against this carcinogenic
activity [67,68]. Human studies have shown that
the ingestion of L. acidophilus or Lactobacillus casei
results in reduced levels of the above enzymes in
the stools of volunteers [69,70]. Whether the
ingestion of probiotics will actually lead to a
reduced incidence of cancer is still unknown, and
such anti-cancer effects must to be demonstrated
in clinical trials involving the use of recognised
cancer markers. A study investigating the impact
of probiotic intake on cancer has shown promis-
ing results [71]. This study demonstrated that use
of L. casei Shirota (present in ‘Yakult’ preparation)
reduced the recurrence rate of superﬁcial bladder
cancer. However, more efﬁcacy studies in
humans are required before deﬁnitive conclusions
can be reached regarding the beneﬁcial effects of
probiotic products in the prevention of cancer.
Allergy
There is evidence to suggest that the composition
of the vaginal microbiota can inﬂuence the even-
tual asthmatic status of children. Benn et al. [72]
demonstrated that vaginal colonisation with
either Ureaplasma urealyticum or staphylococci
during pregnancy was associated with the devel-
opment of wheezing and ⁄ or asthma by the ﬁfth
year of life. However, the use of probiotics in
pregnancy appears to have the effect of reducing
the development of atopic disease in childhood. A
clinical study has shown that giving L. rhamnosus
GG to pregnant women for 4 weeks before deliv-
ery, and then to the newborn infant, caused a
signiﬁcant reduction in the occurrence of early
atopic disease [73]. The ﬁndings from this double-
blinded placebo-controlled study, as well as from
other studies [74], have given more weight to the
possible beneﬁcial effects of probiotics for allergy
sufferers. Furthermore, data from the 4-year
follow-up of the same cohort of infants also
suggest that this protective effect extends beyond
infancy [75]. Although the precise mechanism(s)
is yet to be elucidated, it has been suggested that
lactobacilli may reverse increased intestinal per-
meability, as well as promote gut barrier function,
via the restoration of normal microbiota [73,76]. In
addition, enhancement of the gut-speciﬁc IgA
response and production of cytokines, which
promote IgE antibody production, may occur
[77,78]. With the incidence of allergic conditions,
especially asthma and atopic eczema, increasing,
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particularly in industrialised nations, further
research designed to obtain conclusive results
regarding this promising beneﬁcial effect is
needed.
Genitourinary tract infection
Many women with genitourinary tract infection
may be asymptomatic, and yet be at risk of severe
complications, especially during pregnancy. A
strong link exists between the absence of vaginal
lactobacilli and the risk of sexually transmitted
infection [20,79]. Indeed, a correlation has been
demonstrated between the absence of lactobacilli
in the vagina and positive results for carriage of
Neisseria gonorrhoeae and Chlamydia trachomatis
[80]. Both animal and human studies have shown
that local instillation of lactobacilli resulted in
marked inhibition of Escherichia coli growth, as
well as a reduction in both the severity of
inﬂammation and the risk of recurrent urinary
tract infection [20,81,82]. Furthermore, oral intake
of probiotic lactobacilli has been shown to reduce
the risk of urinary tract infection, bacterial vagi-
nosis and candidiasis [20,79]. Although the mech-
anism by which ingested lactobacilli cause a
reduction in the risk of these infections is unclear,
a multifactorial scenario has been hypothesised in
which it has been suggested that ingested lacto-
bacilli could ascend from the rectal skin to the
vagina, or alternatively, prevent the ascent of
pathogens [20]. However, an overall inﬂuence
of the immune or host system in the reduction
of susceptibility to pathogens could also be
involved. Unfortunately, the evidence for the
efﬁcacy of probiotics in urogenital infections is
still not conclusive, partly because there are still
reports in the scientiﬁc literature that fail to
demonstrate a protective effect against urogenital
infections with the use of probiotics [83–85].
However, the overwhelming body of evidence
remains in support of a beneﬁcial effect.
PROBIOTICS IN HEALTHY
INDIVIDUALS
Many probiotic products are used routinely by
healthy individuals; indeed, the marketing of
many probiotic food products is targeted at
healthy individuals. The claims that regular
ingestion will contribute to a healthy lifestyle,
promote general wellbeing, and protect against or
reduce the risk of developing chronic gastro-
intestinal, respiratory or cardiac problems in the
long-term, has induced many people to undertake
regular consumption of these products. However,
there is no precise measure of ‘health’, and there
are no studies that have veriﬁed the claims that
long-term use of probiotics helps to maintain
good health. In addition, there are no measure-
ments of the impact of probiotics on the immune
system of healthy individuals, or their innate
resistance to disease. It is worth considering
whether probiotic intake has any advantages over
other healthy lifestyle factors such as diet, exer-
cise or stress reduction. It is known that ingestion
of probiotic strains has not been associated with
long-term colonisation and survival in the host, as
probiotic strains are only retained for days or
weeks after discontinuation of ingestion [86–88].
Therefore, their effects appear to be transient, and
continuous long-term intake is necessary. This
raises the question of the impact of regular
probiotic intake on the intestinal ﬂora of healthy
individuals. It is known that there are gut com-
mensal microorganisms that beneﬁt the host, and
the impact of regular intake of probiotics on these
microbes is unknown. Although current evidence
does not indicate loss or depletion of these
beneﬁcial organisms [88], the questions regarding
the long-term effects of probiotic intake on other-
wise healthy individuals remain unanswered.
Well-designed studies are still needed to investi-
gate the perception that healthy people beneﬁt
from regular intake of probiotics.
SAFETY OF PROBIOTICS
As viable probiotic bacteria have to be consumed
in large quantities, and over an extended period
of time for there to be beneﬁcial effects, the issue
of the safety of these organisms becomes a
primary concern. The traditional use of probiotics,
particularly lactobacilli in food processing, with-
out signiﬁcant adverse effects in humans, has
long attested to their safety. In recent years, there
have been reports of isolated cases of opportun-
istic infections caused by certain probiotics, such
as Enterococcus and Saccharomyces spp. Entero-
cocci are of particular medical relevance because
of their increasing importance as a cause of
nosocomial infection, coupled with evolving anti-
microbial resistance. Certain Enterococcus strains
have a long history of safe use as starter cultures
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in dairy fermentation and are therefore being
promoted as probiotics. However, the potential
for genetic transfer of virulence factors from
medical strains to culture starter strains via a
natural conjugation process has now been dem-
onstrated [14]. Current FAO ⁄WHO guidelines [1]
recommend that probiotic strains should be eval-
uated for a number of parameters, including
antibiotic susceptibility patterns, toxin produc-
tion, metabolic and haemolytic activities, infec-
tivity in immunocompromised animal models,
side-effects and adverse incidents in humans.
CHOICE OF PROBIOTIC PRODUCT
AND REGULATORY ISSUES
Although there are guidelines regarding the
choice of probiotic strains and the assessment of
their efﬁcacy and safety [1,16], there is still no
international regulatory consensus, particularly
concerning probiotic food products. Studies eval-
uating products on supermarket shelves have
found that the contents do not always correspond
with the label claims in terms of the type, number
and viability of probiotic microorganisms
[8,9,89,90]. In addition, there is inadequate infor-
mation available regarding the stability of probi-
otics in powdered milk (including infant
formula), especially as the production process is
known to cause cell damage and loss of viability
of the probiotic cultures [91]. Appropriate label-
ling should therefore state the species and strain
of probiotic bacteria in the product as well as the
viable concentration present at the end of the
shelf-life.
CONCLUSIONS
There is scientiﬁc evidence that speciﬁc strains of
probiotic microorganisms confer beneﬁts to the
health of the host and are safe for human use.
However, these cannot be extrapolated to other
strains, as such effects are strain-speciﬁc. Use of
probiotics has potential beneﬁts for conditions
such as gastrointestinal infections, genitourinary
infections, allergies and certain bowel disorders,
all of which afﬂict a considerable proportion of
the global population. However, considerable
work is required to afﬁrm these beneﬁts.
A systematic approach based on the guidelines
recommended by the Joint FAO ⁄WHO Expert
Consultation should be adopted by researchers.
Much work is still needed before credibility can
be given to health claims regarding the use of
probiotic products in healthy individuals. Inter-
nationally uniform regulatory procedures for
probiotic foods are urgently required to ensure
appropriate labelling, manufacturing and hand-
ling procedures, as well as the health claims that
are made for these products.
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